Search

Maryia Zhdanava,1 H Lynn Starr,2 Patrick Lefebvre,1 Todor I Totev,3 Aditi Shah,1 Kristy Sheng,4 Dominic Pilon1 1Analysis Group, Inc, Montréal, Quebec, Canada; 2Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 3Analysis Group, Inc, Boston, MA, USA; 4Analysis Group, Inc, Menlo Park, CA, USACorrespondence: Maryia Zhdanava, Analysis Group, Inc, 1190 avenue des Canadiens-de-Montréal, Suite 1500, Montréal, Quebec, H3B 0G7, Canada, Tel +1 514-394-4469, Email Masha.Zhdanava@analysisgroup.comPurpose: To describe factors that enable the routine use of long-acting injectable antipsychotics (LAIs) for appropriate patients in the current clinical practice, including changes in LAI prescribing due to the COVID-19 pandemic and expectations for prescribing in 2021 in the United States (US).Methods: Frequent LAI prescribers recruited from a nationwide panel in 2020 completed an online survey regarding practice characteristics, perspectives on healthcare system conditions enabling routine use of LAIs, and prescribing patterns and changes in patterns during the COVID-19 pandemic.Results: Of 408 prescribers who completed the survey, 77.7% were physicians and 59.1% had ≥ 10 years of psychiatry practice. More than half of frequent prescribers (57.1%) reported treating > 20% of their patients with schizophrenia with LAIs. The American Psychiatric Association (APA) guideline was followed by 64.0% of prescribers. Most prescribers identified poor adherence to antipsychotics as a circumstance when LAIs are recommended (94.9%) and patient/caregiver involvement in treatment decisions as a key factor impacting the decision to prescribe LAIs (97.3%). Most prescribers reported that LAI prescribing rates were unchanged in 2020 (59.8%). Similar proportions of prescribers expected no change (44.1%) or an increase (42.9%) in LAI prescribing rates in 2021. The number of patients followed, cost of treatment, and availability of staff to administer LAIs were the main driving factors identifi

Maryia Zhdanava,1 H Lynn Starr,2 Todor I Totev,3 Patrick Lefebvre,1 Aditi Shah,1 Kristy Sheng,4 Dominic Pilon1 1Analysis Group, Inc., Montréal, QC, Canada; 2Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 3Analysis Group, Inc., Boston, MA, USA; 4Analysis Group, Inc., Menlo Park, CA, USACorrespondence: Maryia Zhdanava, Manager at Analysis Group, Inc, 1190 Avenue des Canadiens-de-Montréal, Suite, 1500, Montréal, QC, H3B 0G7, Canada, Tel +1 514-394-4469, Email Masha.Zhdanava@analysisgroup.comPurpose: To describe changes due to the COVID-19 pandemic in the prescribing of long-acting antipsychotics (LAI) for schizophrenia, patient outcomes, and patient and healthcare provider (HCP) attitudes regarding COVID-19 vaccination in the United States (US).Methods: An anonymous online survey was administered to US-based LAI prescribers with a psychiatry specialty in May 2021. Information on prescriber and clinical practice characteristics, LAI prescribing, patient outcomes, and attitudes toward COVID-19 vaccination was collected and described.Results: Of the 401 LAI prescribers meeting survey criteria, 64.6% reported that LAI prescribing remained unchanged (increase: 19.2%, decrease: 14.0%). The majority did not switch patients from LAIs to oral antipsychotics (OAP; 63.3%) or to LAI formulations with lower frequency of administration (68.1%); most prescribers switched the same number of patients from OAPs to LAIs during the pandemic as in previous practice (65.1%). Half of LAI prescribers (50.1%) reported antipsychotic adherence as unchanged among most patients; 44.6% reported symptom control/relapse frequency as unchanged. Most prescribers believed their patients with schizophrenia should be prioritized for COVID-19 vaccination (74.1%) and encouraged all patients to obtain a COVID-19 vaccine (84.0%). However, 64.1% of prescribers reported hesitancy among some patients about vaccines’ safety; 51.4% reported that some patients were willing to be vaccinated despite the h